Objective To determine the ominosity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) Systemic Lupus Erythematosus Classification Criteria by determining its predictive role for disease severity in the first 5 years following diagnosis.
Methods 867 patients with systemic lupus erythematosus (SLE) from the Toronto Lupus Clinic were included (all first 12 months after SLE diagnosis). The EULAR/ACR criteria score was calculated based on baseline information. To determine disease severity in the first 5 years after diagnosis, adjusted mean SLE Disease Activity Index 2000 (AMS), flares, remission and immunosuppressive treatment were used as outcomes. The Systemic Lupus International Collaborating Clinics (SLICC) registry comprised the validation cohort.
Results Based on receiver operating characteristic analysis, a EULAR/ACR score of 20 was used as a threshold to compare outcomes between groups. In the first 5 years of disease course, patients with a score of ≥20 had higher AMS scores (p<0.001) and were more likely to ever experience a flare (p<0.001). These patients had lower probabilities of achieving remission and higher requirements for immunosuppressives. Results were confirmed in the SLICC validation cohort. Patients with a score of ≥20 had higher AMS during the first 5 years of disease (5.4 vs 3.1% and ≥20 vs <20 respectively, p≤0.001). The score correlated with AMS (r=0.43, p≤0.001) in the same time frame.
Conclusion A EULAR/ACR score of ≥20 is an indicator of ominosity in SLE. Patients with a score of ≥20 were characterised by a more active disease course throughout the first 5 years. These criteria provide prognostic information regarding disease severity in the first 5 years following diagnosis.
- Systemic lupus erythematosus
- classification criteria
- disease severity
Data availability statement
Data are available upon reasonable request.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Handling editor Josef S Smolen
Presented at This work was presented at the American College of Rheumatology Convergence Meeting, November 2020. Whittall-Garcia L, Gladman D, Urowitz M, Su J, Johnson S. The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE [abstract]. Arthritis Rheumatol 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-new-eular-acr-2019-sle-classification-criteria-defining-ominosity-in-sle/.
Correction notice This article has been corrected since it published Online First. The provenance and peer review statement has been included.
Contributors All authors contributed to the study design, data collection and/or evaluation and critical review of the final manuscript.
Funding Support for this study came from the Lupus Program, Centre for Prognosis Studies in the Rheumatic Diseases. SRJ is supported by a Canadian Institutes of Health Research Award. ZT is supported by a research salary award from the Department of Medicine, University of Toronto.
Competing interests SRJ reports grants from Bayer, Boehringer Ingelheim, Corbus, GSK, Roche, Merck and personal fees from Boehringer Ingelheim and Ikaria.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.